Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-01-30 | Victoria Vakiener Independent Director Age: 59 Director since: 2022 Serves on: •Audit Committee •Nomination Committee The following table sets forth the total compensation paid to our non-employee directors in fiscal 2022. Victoria Vakiener $25,000 Fee Earned or Paid in Cash, $633,793 Stock Awards, Total $658,793. |
| 2024-01-26 | Victoria Vakiener Independent Director Age: 60 Director since: 2022 Serves on: • Audit Committee • Nomination Committee Other Public Company Boards: • Chimerix, Inc. Ms. Vakiener currently serves on the board of directors of Chimerix (NASDAQ: CMRX), a clinical-stage biopharmaceutical company. From November 2018 through September 2021, she served as Chief Commercial Officer of Epizyme, Inc., a biopharmaceutical company that was acquired in 2022, where she built the commercial organization and launched TAZVERIK for two indications within six months. Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson (NYSE: JNJ) for more than twenty years where she held positions of leadership with increasing responsibility across the company’s pharmaceutical and diagnostics businesses. Ms. Vakiener began her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles. Ms. Vakiener received a BS in Biochemistry from Albright College. Ms. Vakiener’s qualifications to serve on the Board include her deep commercial experience and expertise, her scientific development experience, and her board and executive leadership experience. Total compensation paid to our non-employee directors in fiscal 2023: $452,102. |
| 2025-01-29 | Victoria Vakiener Independent Director Age: 61 Serves on: • Nomination Committee (Chair) • Audit Committee Total compensation paid to our non-employee directors in fiscal 2024: $460,833. |
Data sourced from SEC filings. Last updated: 2026-02-03